Avidian Wealth Enterprises LLC Has $1.19 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Avidian Wealth Enterprises LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 1.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 10,003 shares of the company’s stock after selling 151 shares during the period. Avidian Wealth Enterprises LLC’s holdings in Novo Nordisk A/S were worth $1,191,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC raised its holdings in Novo Nordisk A/S by 14.8% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after purchasing an additional 37,346 shares during the last quarter. Private Wealth Partners LLC raised its stake in shares of Novo Nordisk A/S by 155.1% during the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after buying an additional 20,188 shares during the last quarter. Independence Bank of Kentucky lifted its holdings in Novo Nordisk A/S by 192.7% in the third quarter. Independence Bank of Kentucky now owns 11,490 shares of the company’s stock valued at $1,368,000 after buying an additional 7,565 shares during the period. Traynor Capital Management Inc. boosted its stake in Novo Nordisk A/S by 3.4% in the third quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock valued at $36,364,000 after acquiring an additional 10,019 shares during the last quarter. Finally, Cetera Investment Advisers grew its holdings in Novo Nordisk A/S by 453.3% during the 1st quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock worth $34,095,000 after acquiring an additional 217,545 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 4.3 %

NYSE:NVO opened at $105.35 on Thursday. The business has a 50 day moving average price of $122.65 and a two-hundred day moving average price of $130.59. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.46. The company has a market cap of $472.76 billion, a P/E ratio of 36.08, a price-to-earnings-growth ratio of 1.43 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). The company had revenue of $9.82 billion for the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. As a group, analysts expect that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Analyst Ratings Changes

NVO has been the subject of a number of analyst reports. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.